
Leading Pharma & Biotech Journalist Richard Staines Joins Optimum
14 November 2022 - Optimum Strategic Communications ("Optimum"),…

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight
Financing growth: Walking the tightrope
InsightIn the context…

Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program
Agreement enables use of CD8 ImmunoPETTM Imaging Technology…

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases
Industry expert Ulrik Mouritzen M.D. appointed Chief Executive…

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
The companies enter into a license agreement for the European…

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Access to up to $400 million expected to provide cash runway…

Sequana Medical to present at Jefferies London Healthcare Conference
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext…

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy
First-in-human study investigating the safety and immunogenicity…

Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference
We were proud to host a fantastic panel chaired by BioCentury’s…

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
Inobrodib is a pioneering drug targeting twin tumour drivers…

Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK
Consensus group of clinicians have developed a framework…

Novo Holdings acquires KabaFusion from Pritzker Private Capital. KabaFusion’s clinician-led management team will remain significant investors in the business alongside Novo Holdings
Novo Holdings, a leading healthcare investment firm, announced…

Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia
The grant will enable leading international researchers to complete…

AMSilk Invited to Participate in VISION 2045 Summit
Leaders from across the world will convene at VISION 2045 Summit…

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients
Funds will be used to accelerate development of proprietary ambulant…

Top takeaways from Mike Ward’s fireside chat with Werner Lanthaler, CEO of Evotec
We were privileged to hear visionary insights during Mike Ward’s…

ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial
Los Angeles, California, USA, October 25th, 2022 – ImaginAb…

Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
alfapump achieves pre-specified primary effectiveness endpoints…

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022
Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York